Enlarged Prostate Care Has Changed More in the Last Decade Than in the Previous Three: Dr. Jitesh Patel on the Science Behind Modern BPH Treatment

The most common prostate condition in men over fifty is now a precision decision, not a binary one. A board-certified urologist explains how that choice actually gets made.

For most of modern urology, a man with an enlarged prostate faced a narrow set of choices. He could live with worsening symptoms, take medication for the rest of his life, or undergo a major operation that carried real risks to urinary and sexual function. That trade-off, manage it with drugs or accept the side effects of surgery, defined the field for a generation. It no longer does.

Dr. Jitesh Patel, the board-certified urologist who founded and leads Advanced Urology in metro Atlanta, has spent his career at the point where that older model broke down. He earned his medical degree at Temple University School of Medicine and completed a six-year surgical residency at Thomas Jefferson University Hospitals, where he served as chief resident and trained in robotics, laparoscopic surgery, and endourology. Over roughly two decades in practice, he has watched the treatment of benign prostatic hyperplasia, the clinical name for an enlarged prostate, move from a blunt instrument toward something far closer to precision medicine.

The shift did not come from one breakthrough device. It came from a growing set of procedures, each with a different mechanism, recovery profile, and effect on sexual function, and from a more disciplined way of deciding which one belongs to which patient. Understanding that change starts with the condition itself.

A common condition that men rarely talk about

Benign prostatic hyperplasia is the most common prostate problem in men over fifty, according to the National Institute of Diabetes and Digestive and Kidney Diseases. Its footprint widens with age. Autopsy studies summarized in the clinical reference StatPearls find histological evidence of BPH in 50 to 60 percent of men in their sixties and in 80 to 90 percent of those older than seventy. Researchers have estimated roughly 94 million cases worldwide as of 2019.

The biology is straightforward. As men age, hormonal signaling driven largely by dihydrotestosterone prompts the prostate’s transition zone to grow. Because the gland wraps around the urethra, that growth squeezes the channel urine flows through, and the bladder has to work harder to empty. The result is the cluster of complaints urologists group under the term lower urinary tract symptoms, or LUTS: a weak stream, hesitancy, urgency, frequent trips to the bathroom, and the broken sleep of nocturia.

Left unaddressed, the consequences reach beyond inconvenience. The NIDDK notes that untreated obstruction can progress to urinary retention, recurrent infections, bladder stones, and, in severe cases, damage to the bladder and kidneys. Many men delay care because they assume the symptoms are an unavoidable part of aging. They are common, but they are also treatable, and the threshold for treating them has fallen as the procedures have grown safer.

How the problem gets measured before it gets treated

One of the less visible changes in BPH care is how data-driven the diagnosis has become. A workup begins with a medical history and the AUA Symptom Index, a standardized questionnaire that converts vague complaints into a score clinicians can track over time, paired with a urinalysis. Objective measures then fill in the picture: a uroflowmetry test captures peak urinary flow, a post-void residual scan shows how much urine the bladder fails to expel, and imaging establishes prostate size. PSA testing and, when warranted, cystoscopy round out the assessment.

Those numbers matter because they shape the recommendation. Data from the long-running Olmsted County Study identified a prostate volume above 50 milliliters and a low peak flow rate as markers of higher risk for symptom progression and acute urinary retention. A 40-milliliter prostate with a prominent median lobe and a 90-milliliter gland call for different tools, which is why staging precedes any conversation about which procedure to use.

The treatment ladder, from watchful waiting to the operating room

BPH care is best understood as a ladder. At the bottom sit lifestyle adjustments and active surveillance for men whose symptoms are mild. The next rung is medication. Alpha-blockers such as tamsulosin relax smooth muscle in the prostate and bladder neck to ease flow and remain a cornerstone of therapy, while 5-alpha-reductase inhibitors can shrink larger glands over time.

When medication stops working or side effects mount, the conversation turns surgical. For decades the reference standard has been transurethral resection of the prostate, or TURP, in which obstructing tissue is removed through the urethra. The American Urological Association still measures newer procedures against it. TURP is effective, but it is not free of consequences, and the history of the field is in part a story of trying to match its results with less collateral damage. A generation ago, TURP filled roughly half of a urologist’s surgical schedule. The arrival of effective drugs in the 1980s pushed care toward a medication-first model, and the procedures that followed aimed to occupy the space in between.

The middle ground that changed the field

That space is now filled by a category the AUA calls minimally invasive surgical therapy, or MIST. The best known options, the prostatic urethral lift marketed as UroLift, water vapor thermal therapy, and the temporarily implanted nitinol device known as iTIND, are FDA-cleared, can be performed in an office setting under local anesthesia, and share one defining trait. Unlike TURP and laser procedures, they do not cut away prostate tissue.

They reach the same goal by different routes:

• Prostatic urethral lift places permanent implants that pull the enlarged lobes apart and hold the urethra open, without heating or removing tissue.
• Water vapor thermal therapy uses radiofrequency energy to generate steam, delivered into the prostate to destroy a targeted volume of tissue that the body then reabsorbs, shrinking the gland over several weeks.
• The temporarily implanted nitinol device is positioned for a few days to reshape the channel, then removed.

The evidence behind these procedures has matured. A 2024 systematic review pooling 1,864 patients across thirteen studies found that all three produced significant gains in peak flow and symptom scores, with sexual function largely preserved. That last point is the crux of why MIST reshaped the field. As one AUA presentation framed it, the sexual side effects that accompany traditional ablative surgery, including retrograde ejaculation and erectile dysfunction, are markedly lower with these approaches. The updated AUA guidance reflects this directly: men who prioritize preserving ejaculatory and erectile function may be offered prostatic urethral lift, and water vapor therapy is indicated for the same goal.

Why “which procedure is best” is the wrong question

The temptation, for patients and marketers alike, is to crown a single best procedure. Urologists who do this work daily tend to resist that framing. The right choice depends on a set of variables that differ from one man to the next: the size and shape of the prostate, whether a median lobe is obstructing the bladder neck, the severity of symptoms, how much a patient values preserving ejaculatory function, and his tolerance for the possibility of needing another procedure later.

The guidelines build that nuance in. The AUA frames treatment selection as a shared decision between physician and patient, one that should include a candid discussion of the chance a procedure fails and requires retreatment. For very large glands, size-independent options such as holmium or thulium laser enucleation, which remove the obstructing tissue whole, may prove more durable than a MIST procedure that would leave too much tissue behind. Matching the modality to the anatomy is where clinical experience earns its keep.

“The first question I ask is not which procedure, it is what does this particular prostate look like and what does this particular man want to protect. A 100-gram gland with a large median lobe and a 45-gram gland in a patient determined to preserve ejaculation are two different problems. The technology only helps if you match it to the anatomy in front of you.”

DR. JITESH PATEL, FOUNDER AND PRESIDENT, ADVANCED UROLOGY

What smarter, earlier intervention means for patients

The gentler side-effect profile of newer procedures has done more than lengthen the menu. It has lowered the threshold for acting at all. Older evidence, including a frequently cited 1998 analysis, found that men who undergo intervention earlier in the course of BPH tend to improve more than those who wait until the bladder has been straining for years. When a procedure can be done in an office, under local anesthesia, with sexual function intact, the calculus of when to treat shifts.

At Advanced Urology, that calculus plays out inside an integrated model the practice has built, with diagnostics, imaging, the procedure itself, and follow-up coordinated under one roof rather than scattered across referrals.

“For years, men were told to wait until things got bad enough to justify surgery. That logic made sense when the only options carried heavy side effects. It does not anymore. When we can evaluate, image, and treat a patient inside one coordinated program, we can step in earlier and use the least invasive option that will actually relieve the obstruction, before the bladder pays the price.”

DR. JITESH PATEL, FOUNDER AND PRESIDENT, ADVANCED UROLOGY

The transformation in BPH care over the past decade is easy to miss because it did not arrive as a single headline. It came as a steady accumulation of better-targeted tools and a more rigorous way of choosing among them. For a condition most men will eventually face, the practical effect is significant. The question has moved from whether to endure an enlarged prostate or risk the side effects of fixing it, to which precise approach fits a particular patient’s anatomy and life. That is a quieter kind of progress, and for the men it serves, a meaningful one.